|
| Press Releases |
|
 |
|
| Wednesday, June 2, 2021 |
|
|
エーザイ、人事異動（2021年6月1日付）を発表 |
| エーザイ株式会社は本日、人事異動（2021年6月1日付）を発表しました。 more info >> |
|
| Wednesday, November 20, 2024 |
|
|
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements |
| Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor "TASFYGO Tablets 35mg" (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. more info >> |
|
| Friday, November 15, 2024 |
|
|
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) |
| Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be broadcast nationwide in Japan from November 15 with the aim of increasing public understanding of MCI (Mild Cognitive Impairment). more info >> |
|
|
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab. more info >> |
|
| Tuesday, November 5, 2024 |
|
|
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem" |
| Eisai Co., Ltd. and Eisai's corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai Innovation,Inc. has been selected as a registered venture capital (Registered VC) of the Strengthening Program for Pharmaceutical Startup Ecosystem implemented by the Japan Agency for Medical Research and Development (AMED). more info >> |
|
| Friday, November 1, 2024 |
|
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). more info >> |
|
| Thursday, October 31, 2024 |
|
|
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Clinical Trials for Alzheimer's Disease Conference (CTAD), held in Madrid, Spain, and virtually. more info >> |
|
|
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) |
| Eisai Co. Ltd announced today that the latest findings on anti-MTBR (microtubule binding region) tau antibody E2814 were presented at the 17th annual Clinical Trials on Alzheimer's Disease (CTAD) conference, held in Madrid, Spain, and virtually. more info >> |
|
| Thursday, October 17, 2024 |
|
|
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association |
| Shimadzu Corporation, Eisai Co., Ltd., Oita University, and Usuki City Medical Association have demonstrated the utility of blood biomarkers in predicting the accumulation of amyloid beta (Abeta)(1) in the brain, a noted cause of Alzheimer's disease(2), in a cohort study conducted in Usuki City, Oita from November 2022. more info >> |
|
| Thursday, August 5, 2021 |
|
|
エーザイ、第37回企業広報賞「企業広報大賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、一般社団法人日本経済団体連合会（東京都）の関連団体である一般財団法人経済広報センター（東京都、会長：十倉雅和）が主催する第37回企業広報賞において、「企業広報大賞」を受賞しましたのでお知らせします。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Baguio Wins Two Contracts for Smart Food Waste Recycling Machines and Smart Balances from EPD
Jan 20, 2025 21:20 HKT/SGT
|
|
|
碧瑶赢得环保署智能厨余回收机及智能磅两份合约
Jan 20, 2025 21:12 HKT/SGT
|
|
|
碧瑤贏得環保署智能廚餘回收機及智能磅兩份合約
Jan 20, 2025 20:41 HKT/SGT
|
|
|
DENSO Exhibits at Bharat Mobility Global Expo 2025, New Delhi
Jan 20, 2025 20:26 JST
|
|
|
Transforming Philippine Healthcare: The 2025 Philippine Hospital & Healthcare Digitalization Summit
Jan 20, 2025 16:59 HKT/SGT
|
|
|
Q2 Metals Announces Details of its Expansion Drill Program for the Cisco Lithium Project in Eeyou Istchee James Bay, Quebec
Jan 20, 2025 16:05 HKT/SGT
|
|
|
Celebrate Chinese New Year with Vibrant Festivities at Spritzer EcoPark
Jan 20, 2025 15:30 HKT/SGT
|
|
|
三菱重工、人事異動を発表
Jan 20, 2025 15:30: JST
|
|
|
Hitachi Acquires a Sales and Maintenance Service Company for Large Motors in the United States
Jan 20, 2025 15:07 JST
|
|
|
三菱造船とTPFC、タブレット端末を利用したポータブル運航支援システム「ナビン」のリース販売を開始
Jan 20, 2025 14:00: JST
|
|
|
Suzuki's First BEV "e VITARA" Adopts eAxle
Jan 20, 2025 13:58 JST
|
|
|
Honda、「FREED e:HEV｣を一部改良
Jan 20, 2025 11:20: JST
|
|
|
Green Rain Solar Inc.（現代公司 The Now Corporation (OTC:NWPN) 的子公司）宣布推出帶有整合灌溉和備用電力系統的自給式太陽能溫室
Jan 20, 2025 11:00 HKT/SGT
|
|
|
Hypertec Cloud 與 Potentia 合作推動可持續 AI 雲端擴展，在北美新增 480MW 的平衡容量
Jan 20, 2025 11:00 HKT/SGT
|
|
|
Honda Presents the World Premier of BF300 Large-size Outboard Motor at the Dusseldorf Boat Show 2025
Jan 20, 2025 11:36 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
